Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass (GLIMMER)

University of Alberta

Status: Not yet enrolling

Conditions: Semaglutide; Obesity; Type 2 Diabetes

Study type: Observational

Funder types: Other

Identifiers

NCT07272837

Pro00153724

Details and patient eligibility

About

The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss.

This study involves (3) in-person study visits. At each visit, participants will be asked to:

• Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs.
• Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength.
• Complete questionnaires (related to demographics, health information, physical activity, and nutrition).
• Have a blood sample collected.
• Have blood ketone levels assessed through two finger pricks.
• Complete three days of food records.

Enrollment: 50 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults 18-75 years of age
• Starting semaglutide for type 2 diabetes or weight loss (body mass index ≥27.5kg/m2)
• Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment)

Exclusion criteria

• Current use of semaglutide for more than 2 weeks
• Major recent heart issues or other severe health conditions
• Concerns related to MRI use (including metal implants, pacemaker, severe claustrophobia)